Beone Medicines Ltd.
An oncology-focused biopharmaceutical company that develops and sells medicines for blood cancers, including Brukinsa, used to treat leukemia and lymphoma. Founded in Beijing in 2010 by John Oyler and Xiaodong Wang, it was originally called BeiGene — a blend of "Beijing" and "gene" — before rebranding as BeOne in 2024, a name chosen to reflect its mission against cancer: "Be" stands for patients' goal to be free of disease, and "One" for uniting people in that fight.
American Depositary Receipt (each representing 13 ordinary shares)
Bought 3.85M
Sold 22.00M
Granted 12.12M · Sold 3.63M
Bought 9.10M
Granted 30.22M · Bought 165.5K
Granted 1.47M · Sold 872.7K
Granted 14.92M · Bought 7.79M · Sold 4.51M
Granted 2.59M · Sold 38.9K
Granted 63.0K · Sold 245.1K
Granted 1.81M · Bought 65.0K · Sold 232.1K
Granted 3.28M · Sold 386.8K
Granted 485.0K · Sold 10.0K
Granted 410.1K · Sold 5.3K
Granted 422.8K · Sold 46.3K
Granted 404.6K · Sold 69.4K
Granted 660.9K · Sold 171.0K
Bought 130.0K
Granted 85.2K · Sold 698
Granted 83.7K
Granted 75.9K · Sold 212
Granted 75.9K · Sold 212
Granted 70.0K · Sold 6.1K
Granted 46.3K
Granted 46.7K · Bought 30.0K
Granted 74.0K · Sold 235
Granted 19.0K
Granted 46.0K · Sold 29.6K
Granted 7.8K
Granted 19.0K
Granted 38.1K
Granted 421.6K · Sold 1.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +6 co-filersDirector, 10% owner · 17 transactions | — | 160.04Mas of Oct 2017 | — | 3.85M | — |
| HHLR Advisors, LTD. +1 co-filer10% owner · 10 transactions | — | 125.05Mas of Dec 2024 | — | — | 22.00M |
| Oyler JohnChief Executive Officer, Director · 716 transactions | — | 95.85M | 12.12M | — | 3.63M |
| Hillhouse Capital Management, Ltd.10% owner · 2 transactions | — | 71.14Mas of Feb 2018 | — | 9.10M | — |
| CB Biotech Investment Ltd +3 co-filers10% owner · 1 transaction | — | 19.60Mas of Feb 2016 | — | — | — |
| Amgen Inc10% owner · 12 transactions | — | 18.94Mas of Sep 2021 | 30.22M | 165.5K | — |
| Wang XiaodongDirector, Chair, Scientific Advisory Brd · 305 transactions | — | 14.82M | 1.47M | — | 872.7K |
| Baker Bros. Advisors LP +5 co-filersDirector · 44 transactions | — | 8.54M | 14.92M | 7.79M | 4.51M |
| Merck Sharp & Dohme Corp. +2 co-filers10% owner · 3 transactions | — | 5.13Mas of Feb 2016 | — | — | — |
| Wang LaiPresident, Global Head of R&D · 62 transactions | — | 2.88M | 2.59M | — | 38.9K |
| Glazer Donald W.Director · 41 transactions | — | 2.72Mas of Jun 2024 | 63.0K | — | 245.1K |
| Liang HowardCFO & Chief Strategy Officer · 73 transactions | — | 1.55Mas of Jun 2021 | 1.81M | 65.0K | 232.1K |
| Wu XiaobinPresident and COO · 173 transactions | — | 1.29M | 3.28M | — | 386.8K |
| Li JiEVP and Gl. Head of Bus. Dev. · 8 transactions | — | 475.0Kas of Mar 2018 | 485.0K | — | 10.0K |
| Wang Julia AijunChief Financial Officer · 18 transactions | — | 426.6Kas of Jul 2024 | 410.1K | — | 5.3K |
| Lee Chan HenrySVP, General Counsel · 79 transactions | — | 338.9K | 422.8K | — | 46.3K |
| Peterson Amy C.CMO, Immuno-oncology · 46 transactions | — | 194.6Kas of Dec 2018 | 404.6K | — | 69.4K |
| Huang JaneCMO, Hematology · 253 transactions | — | 160.1Kas of Dec 2021 | 660.9K | — | 171.0K |
| Yuan RuiRongChief Medical Officer · 1 transaction | — | 130.0Kas of Feb 2016 | — | 130.0K | — |
| Ball Titus B.Principal Accounting Officer · 10 transactions | — | 99.6K | 85.2K | — | 698 |
| Hooper Anthony CDirector · 6 transactions | — | 83.7K | 83.7K | — | — |
| Dugan MargaretDirector · 6 transactions | — | 73.2K | 75.9K | — | 212 |
| Riva AlessandroDirector · 6 transactions | — | 73.2K | 75.9K | — | 212 |
| Sanders Corazon (Corsee) D.Director · 13 transactions | — | 54.5K | 70.0K | — | 6.1K |
| Brandicourt OlivierDirector · 3 transactions | — | 46.3K | 46.3K | — | — |
| Malley ThomasDirector · 5 transactions | — | 30.0Kas of Jun 2023 | 46.7K | 30.0K | — |
| Yi QingqingDirector · 10 transactions | — | 24.3K | 74.0K | — | 235 |
| Mooney Elizabeth FisherDirector · 1 transaction | — | 19.0K | 19.0K | — | — |
| Chen Timothy Yung-ChengDirector · 40 transactions | — | 7.8Kas of Jun 2021 | 46.0K | — | 29.6K |
| su Jingshyh SDirector · 1 transaction | — | 7.8Kas of Jun 2021 | 7.8K | — | — |
| Sawyers Charles LazelleDirector · 1 transaction | — | 1.9K | 19.0K | — | — |
| Sharp ShaliniDirector · 3 transactions | — | 9 | 38.1K | — | — |
| Rosenberg AaronChief Financial Officer · 8 transactions | — | 0 | 421.6K | — | 1.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -11.12M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.